Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hologic Adds Vessel Sealing Tech By Acquiring Bolder Surgical For $160M

Executive Summary

Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.

You may also be interested in...

Digital Health Roundup: Black Friday Hits – Digital Twins, Biowearables, Robotics, Cardiology

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona.

News We’re Watching: 3M Names Spin-Off, Boston Scientific Closes Relievant Deal, Mammogen Hits CLIA Milestone, And More

Medtech Insight's News We're Watching highlights medtech industry news developments from the last week that you may have missed. Pantheon Vision announced plans to develop a bioengineered corneal implant, 3M gave a name to its health care spin-off company, Boston Scientific closed its $850m+ deal to buy Relievant Medsystems, Mammogen announced plans to launch its genTRU breast cancer test to align with the Mammography Quality Standards Act, and Medtronic touted another successful demonstration of its spinal cord stimulation technology.

Cardio Catch-Up: Registry Data Spurs Discussion On TAVR For Asymptomatic Patients

Results from the TVT Registry suggest that TAVR may benefit patients who have severe aortic disease but few symptoms. Clinical trials specifically designed to answer that question are needed, according to an editorial in JACC


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts